E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healthy adult volunteers, healthy patients undergoing surgery under general anesthesia, and patients in a state of inflammation after having undergone surgery under general anaesthesia (within 24 hrs after the end of the surgery). |
Friska människor, friska patienter som genomgår kirurgi under narkos, och patienter med inflammation som just har genomgått kirurgi (inom 24 timmar före prövningen) |
|
E.1.1.1 | Medical condition in easily understood language |
Healthy adults in the conscious state. Patients undergoing surgery and who do not have inflammatory disease. Patients who have just undergone surgery and who are in a state of inflammation.
|
Se ovan. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physiological processes [G07] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To study if hyperoncotic albumin can attract interstitial fluid under three circumstances - conscious, anesthetized state, and anesthetized state in patients with inflammation.
|
Att studera om hyperonkotiskt albumin givet intravenöst kan translokera vätska till interstitiella rummet om det ges intravenöst.
|
|
E.2.2 | Secondary objectives of the trial |
Half-life of plasma volume expansion. Plasma half-life of infused albumin. |
Hur snabbt försvinner plasmavolymsexpansionen? Hur snabbt försvinner albuminet från blodbanan? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Healthy volunteers. Healthy patients undergoing lengthy surgery with expected small hemorrhage. Patients scheduled for lengthy surgery who have inflammatory disease with expected small hemorrhage. |
|
E.4 | Principal exclusion criteria |
Patients with serious cardiac or pulmonary disease. Health stats corresponding to American Society of Anesthersiologists (ASA) Group III and IV. Inability to understand Swedish. Dementia. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The data collection is completed 4 hours after the 30-min infusion of albumin is initiated. |
Datainsamlingen avslutas 4 timmar efter det att 30-minutersinfusionen av albumin påbörjats. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The study is always ended at 4 hours. |
|
E.5.2 | Secondary end point(s) |
Collection of data for calculation of the duration of the plasma volume expansion and the plasma half-life of albumin is also ended at 4 hours after the infusion starts. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At the end of the study, 4 hours after the infusion was initiated. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end if serious adverse effects appear. This is unlikely, as albumin 20% is used worldwide and is only known to be associated with a low risk of allergic reactions. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |